50.46
Moonlake Immunotherapeutics stock is traded at $50.46, with a volume of 1.18M.
It is down -3.61% in the last 24 hours and up +6.91% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$52.35
Open:
$52.46
24h Volume:
1.18M
Relative Volume:
2.27
Market Cap:
$3.20B
Revenue:
-
Net Income/Loss:
$-145.21M
P/E Ratio:
-21.94
EPS:
-2.3
Net Cash Flow:
$-140.12M
1W Performance:
-9.47%
1M Performance:
+6.91%
6M Performance:
+7.09%
1Y Performance:
+22.30%
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MLTX
Moonlake Immunotherapeutics
|
50.46 | 3.32B | 0 | -145.21M | -140.12M | -2.30 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
598.89 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
299.94 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
Nov-05-24 | Resumed | Wedbush | Outperform |
Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Jun-25-24 | Initiated | Oppenheimer | Outperform |
Apr-02-24 | Initiated | Goldman | Neutral |
Feb-15-24 | Initiated | Wolfe Research | Outperform |
Dec-08-23 | Initiated | Citigroup | Buy |
Nov-02-23 | Initiated | Stifel | Buy |
Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
Aug-31-23 | Initiated | Needham | Buy |
Jun-15-23 | Initiated | Barclays | Equal Weight |
May-01-23 | Initiated | Guggenheim | Buy |
Mar-22-23 | Initiated | Wedbush | Outperform |
Mar-09-23 | Initiated | BTIG Research | Buy |
Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
Feb-02-23 | Initiated | Bryan Garnier | Buy |
Nov-11-22 | Initiated | Jefferies | Buy |
Aug-25-22 | Initiated | SVB Leerink | Outperform |
Jul-21-22 | Initiated | H.C. Wainwright | Buy |
Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
MoonLake Immunotherapeutics Inches Toward Key Resistance — Will It BreakEntry Plan for Oversold Reversal Stocks Released - metal.it
Is Now a Good Time to Reenter MoonLake ImmunotherapeuticsSwing Trade Entry With Volume Triggers Released - metal.it
Published on: 2025-07-29 20:29:47 - beatles.ru
Promising Outlook for MoonLake Immunotherapeutics: Buy Rating Backed by Strong Position in Hidradenitis Suppurativa Treatment - TipRanks
What does MLTX's flat EPS in 2024 suggest for investors? - AInvest
Does MoonLake Immunotherapeutics stock perform well during market downturnsStock Market Data Feed For Consistent Profits - jammulinksnews.com
Published on: 2025-07-29 08:56:36 - metal.it
MoonLake Immunotherapeutics Company’s Quarterly Earnings Growth: What the Numbers SayWealth Building Stock Market Ideas Based on Momentum - metal.it
Published on: 2025-07-29 07:59:51 - metal.it
Published on: 2025-07-29 06:35:51 - metal.it
What institutional investors are buying MoonLake Immunotherapeutics stockFast-track wealth growth - jammulinksnews.com
Is MoonLake Immunotherapeutics stock overvalued or undervaluedTake advantage of unprecedented market momentum - jammulinksnews.com
How does MoonLake Immunotherapeutics generate profit in a changing economyFree Stock Market Trend Analysis - jammulinksnews.com
How strong is MoonLake Immunotherapeutics company’s balance sheetAchieve explosive financial results today - jammulinksnews.com
How does MoonLake Immunotherapeutics compare to its industry peersInvest smarter with advanced market data - jammulinksnews.com
What catalysts could drive MoonLake Immunotherapeutics stock higher in 2025Invest confidently with professional advice - jammulinksnews.com
What are MoonLake Immunotherapeutics company’s key revenue driversBuild a diversified portfolio for stability - jammulinksnews.com
Does MoonLake Immunotherapeutics (NASDAQ:MLTX) Have A Healthy Balance Sheet? - 富途牛牛
What analysts say about MoonLake Immunotherapeutics stockMarket-leading profit generation - Autocar Professional
MoonLake Immunotherapeutics Stock Analysis and ForecastUnbelievable profit margins - PrintWeekIndia
Is MoonLake Immunotherapeutics a good long term investmentBreakthrough stock performance - jammulinksnews.com
Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal - insights.citeline.com
MoonLake Immunotherapeutics: Promising Phase 3 Trials and Market Potential for Sonelokimab - TipRanks
What drives MoonLake Immunotherapeutics stock priceExplosive capital gains - jammulinksnews.com
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moonlake Immunotherapeutics Stock (MLTX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Moukheibir Catherine | Director |
Jul 03 '25 |
Sale |
48.79 |
23,500 |
1,146,565 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):